Mark Stenhouse
Officer at Prometheus Biosciences, Inc. (RXDX)
Mark Stenhouse has filed 11 insider reports with the SEC since May 2021, as director at Phathom Pharmaceuticals, Inc. (PHAT) and officer at Prometheus Biosciences, Inc. (RXDX). The latest filing, on May 21, 2026, reports grant or award at Phathom Pharmaceuticals, Inc. (PHAT).
- Filings
- 11
- Companies
- 2
- Bought on market
- None
- Sold on market
- None
Companies where Mark Stenhouse is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 54,122 | $4.66 | May 21, 2026 | ||||
| Officer | 0 | Jun 16, 2023 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- May 19, 2026PHATDirector Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 unitsForm 4Grant or award
- Jun 3, 2025PHATDirector Stenhouse Mark was granted 10,500 shares, increasing direct ownership by 54% to 30,000 unitsForm 4Grant or award
- May 23, 2024PHATStenhouse Mark was granted 10,500 shares, increasing direct ownership by 117% to 19,500 unitsForm 4Grant or award
- Jun 16, 2023RXDXSEC Form 4 filed by Stenhouse MarkForm 4Sale back to the company
- Jun 1, 2023RXDXSEC Form 4 filed by Stenhouse MarkForm 4Other acquisition or disposition
- May 25, 2023PHATSEC Form 4 filed by Stenhouse MarkForm 4Grant or award
- Dec 9, 2022RXDXSEC Form 4: Stenhouse Mark was granted 9,811 shares, increasing direct ownership by 59% to 26,442 unitsForm 4Grant or award
- May 25, 2022PHATSEC Form 4 filed by Stenhouse MarkForm 4Grant or award
- May 20, 2022RXDXSEC Form 4 filed by Stenhouse MarkForm 4Grant or award
- Nov 14, 2021RXDXSEC Form 4 filed by Stenhouse MarkForm 4Grant or award
- May 21, 2021PHATSEC Form 4 filed by Stenhouse MarkForm 4Grant or award
Compare Mark Stenhouse with
- Mark Stenhouse vs Robert Charles Breedlove1 shared
- Mark Stenhouse vs Asit Parikh1 shared
- Mark Stenhouse vs Heidi Fields1 shared
- Mark Stenhouse vs James N Topper1 shared
- Mark Stenhouse vs Theodore R Schroeder1 shared
- Mark Stenhouse vs Michael F Cola1 shared
Other insiders at the same companies
- Robert Charles BreedlovePHAT
- Asit ParikhPHAT
- Heidi FieldsPHAT
- James N TopperPHAT
- Frank KarbePHAT
- Theodore R SchroederPHAT
- Michael F ColaPHAT
- Anne Marie CookPHAT
- Steven L BastaPHAT
- Sanjeev NarulaPHAT
- Molly HendersonPHAT
- Terrie CurranPHAT
- Azmi NabulsiPHAT
Questions about Mark Stenhouse
- What is Mark Stenhouse's role at Prometheus Biosciences, Inc.?
- Mark Stenhouse reports to the SEC as officer at Prometheus Biosciences, Inc. (RXDX), according to the latest filing on June 16, 2023. Mark Stenhouse has also filed as director at Phathom Pharmaceuticals, Inc. (PHAT).
- How many shares does Mark Stenhouse own?
- After the latest filing that states it, Mark Stenhouse directly owned 54,122 shares of Phathom Pharmaceuticals, Inc. (PHAT). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Mark Stenhouse bought or sold stock recently?
- No open-market purchases or sales by Mark Stenhouse are on file. The filings report grant or award, sale back to the company and other acquisition or disposition.
- How do I get alerts when Mark Stenhouse files?
- Follow Mark Stenhouse on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark Stenhouse (SEC CIK 0001734751). Totals count each trade once, skipping amendments whose original is on file, from May 24, 2021 on. View on SEC EDGAR · Get this as JSON